A migraine is more than
just a bad headache or an inconvenience. The typical effects
of migraine, such as intense headache, sensitivity to light
and sound, and even vomiting, can disrupt your life. If
you’re not getting the complete relief you need, it may
be time to consider MIGRANAL® (dihydroergotamine mesylate).
You Don't Have to Live with Migraine Pain
MIGRANAL simultaneously works on two different causes of migraine pain – meaning
it provides lasting, not temporary, relief.
You Don’t
Have to Wait to Treat
MIGRANAL, unlike other medications, can be used anytime
during a migraine attack for relief. You can use it at
the onset of
an attack, in the middle of an attack, or even if you wake
up with a migraine.
Reduce Next-Day Migraine Risk
86% of patients who’ve taken MIGRANAL are migraine –free
up to 24 hours after treatment.
Learn more about migraines, MIGRANAL, and why you no longer
have to live with the pain.
DID YOU KNOW?
Most migraines are morning migraines. That
is, they usually occur between the hours of
5am – 8am, causing people to usually wake up in pain. Typically medication
is not taken in these cases as most migraine medicines won’t work if taken
too late during an attack. But MIGRANAL is different and works anytime —even
if taken during an attack.
IMPORTANT SAFETY INFORMATION:
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.
Migranal Nasal Spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina. Migranal also should not be given to patients with uncontrolled hypertension, patients who have used 5-HT1 agonists, ergotamine-containing or ergot-type medications or methysergide within the last 24 hours, or patients with hemiplegic or basilar migraine. Migranal Nasal Spray is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. Migranal Nasal Spray should not be administered to pregnant women or nursing mothers.
Serious cardiac events, including some that have been fatal, have occurred following use of DHE 45 but are extremely rare. During clinical studies and the foreign postmarketing experience with Migranal Nasal Spray, there have been no fatalities due to cardiac events.
The most commonly reported adverse events in clinical trials for Migranal Nasal Spray were rhinitis, altered sense of taste, application site reactions, dizziness, nausea and vomiting. Adverse events associated with discontinuation were rhinitis, dizziness, facial edema, cold sweats, accidental trauma, depression, elective surgery, somnolence, allergy, vomiting, hypotension, and paresthesia.
